The Catalan company specializing in medicines derived from plasma Grifols A announced on Thursday the signing of an agreement with Canadian Plasma Resources (CPR), a Canadian plasma collector authorized by Health Canada, based on donations to Grifols A Have the right to receive donated plasma. CPR Center. Grifols is looking to acquire the CPR centers by the end of 2025.
In addition to your agreement with CPR, Grifols also plans to open its own plasma donation center in Canada expanding the number by early 2022 following the acquisition of the first one in Winnipeg, Manitoba, and another that is currently in development in Edmonton, Alberta.
intend to open Up to five additional centers in the country And potential locations are being explored in Ontario, where Grifols would serve as an “agent” for Canadian Blood Services by exemption under the province’s Voluntary Blood Donation Act.
The exact location of Ontario centers will also depend on criteria such as population density, local talent and transportation links, subject to prior approval by Canadian Blood Services. The Alberta and Ontario centers are expected to be operational in 2024. There are currently no plans to establish a center in British Columbia.
Plasma grifols collected in Canada will support the company’s long-term collaboration agreement with Canadian Blood Services, announced in September 2022, to increase Canada’s immunoglobulin (Ig) self-sufficiency entirely through Canada.
Grifols is working with Canadian Blood Services to continually increase the supply of Canadian plasma needed for the volume to eventually reach the 600,000 liters agreed upon for manufacture. 2.4 million grams of treatment per year With Ig in 2026. Production will go exclusively to Canadian Blood Services and Canadian patients.
“Grifols is moving full speed ahead on its commitment to Canadian Blood Services, helping Canada achieve plasma self-sufficiency for the benefit of patients who rely on essential plasma therapies,” said Raimon Grifols, the company’s Corporate CEO. Are.” “We make sure that all Canadian plasma we get is made in Canada and turned into medicines in the country to help patients in Canada.”
Grifols’s latest movements Over Three Decades of Commitment to Canada and their patients who rely on the company’s products.
In 2020, Grifols invested more than $400 million in its production complex in Montreal, which includes a plasma fractionation plant with a capacity of 1.5 million liters of fraction and two purification plants. The facility, which will produce Ig for Canadian Blood Services, represents Canada’s first and only large-scale plasma fractionation complex.
